Day One Biopharmaceuticals
DAWN
DAWN was delisted on the 22nd of April, 2026.
58 hedge funds and large institutions have $698M invested in Day One Biopharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 25 increasing their positions, 5 reducing their positions, and 5 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 5
260% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 5
54% more capital invested
Capital invested by funds: $453M → $698M (+$245M)
36.14% more ownership
Funds ownership: 30.83% → 66.97% (+36%)
29% more funds holding
Funds holding: 45 → 58 (+13)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$45.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$13.7M |
| 3 |
DM
Deerfield Management
New York
|
+$10.1M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$7.62M |
| 5 |
PCM
Pathway Capital Management
Irvine,
California
|
+$4.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$4.22M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$1.11M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$416K |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$308K |
| 5 |
MIM
MetLife Investment Management
Whippany,
New Jersey
|
-$114K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SO
51
STRS Ohio
Columbus,
Ohio
| $42K | – | – | – |
|
52
Legal & General Group
London,
United Kingdom
| $17K | – | – | – |
|
|
TRCT
53
Tower Research Capital (TRC)
New York
| $17K | +$10.5K | +513 | +96% |
|
|
AIP
54
Ameritas Investment Partners
Lincoln,
Nebraska
| $14K | – | – | – |
|
|
CAL
55
Capital Analysts LLC
Fort Washington,
Pennsylvania
| $13K | – | – | – |
|
56
Daiwa Securities Group
Tokyo,
Japan
| $3K | +$3.72K | +181 | New |
|
|
HNWAG
57
High Net Worth Advisory Group
Naples,
Florida
| $3K | +$4.11K | +200 | New |
|
|
58
Millennium Management
New York
| – | -$4.22M | -177,945 | Closed |
|
|
MIM
59
MetLife Investment Management
Whippany,
New Jersey
| – | -$114K | -4,806 | Closed |
|
|
MLICM
60
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$86.3K | -3,636 | Closed |
|
|
JCM
61
Jacobi Capital Management
Pittston,
Pennsylvania
| – | -$5K | -200 | Closed |
|
|
RTL
62
Red Tortoise LLC
Atlanta,
Georgia
| – | -$4K | -196 | Closed |
|
63
Kayne Anderson Rudnick Investment Management
Los Angeles,
California
| – | +$103 | +5 | New |
|
DAWN Hedge Fund Activity: Q4 2021 in Review
58 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Day One Biopharmaceuticals (DAWN) for Q4 2021, worth a combined $698M — up 54% from $453M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new DAWN positions and 5 closed out — a net gain of 13 holders — while 25 added to existing stakes and 5 trimmed.
The largest buyer was Vanguard Group, adding an estimated $45.5M. The largest seller was Millennium Management, exiting entirely with an estimated $4.22M sold.
- 58 institutional investors held Day One Biopharmaceuticals (DAWN) as of Q4 2021, up from 45 in Q3 2021.
- Funds reported $698M of Day One Biopharmaceuticals stock for Q4 2021, up 54% quarter-over-quarter.
- 18 funds opened new Day One Biopharmaceuticals positions in Q4 2021 and 5 closed out, a net change of +13 holders.
- The largest Day One Biopharmaceuticals buyer in Q4 2021 was Vanguard Group, an estimated $45.5M added.
- The largest Day One Biopharmaceuticals seller in Q4 2021 was Millennium Management, an estimated $4.22M sold.
Based on aggregated 13F filings for Q4 2021.